U.S. Metals and Mining Stock News

ANI Pharmaceuticals (NasdaqGM:ANIP) has launched Carbamazepine Extended-Release Capsules, a limited competition generic version of Carbatrol. The company also reported publication of Phase 4 clinical trial results for ILUVIEN in a leading ophthalmology journal. These updates expand ANI's presence in specialty generics and reinforce its role in high-value therapeutic areas. ANI Pharmaceuticals enters this news cycle with its shares at $76.48 and a 1 year return of 10.5%. Over the past 3...

Heartland Advisors named EOG Resources (NYSE:EOG) a top contributor for Q1 2026. The recognition was tied to portfolio milestones across domestic and international assets. Heartland also highlighted EOG’s dividend and share buyback activities as key drivers of shareholder cash returns. EOG Resources, an exploration and production company listed on the NYSE under the ticker EOG, is at the center of the ongoing debate around capital discipline in oil and gas. Investors have been watching how...

Latest Quarter Sets the Stage for Wells Fargo's Earnings Story Wells Fargo (WFC) opened 2026 with Q1 revenue of US$20.3b and basic EPS of US$1.62, against a trailing twelve month EPS of US$6.55 and net income of US$20.7b, giving investors a clear read on both the quarter and the broader earnings run rate. Over recent periods, revenue has moved from US$19.3b in Q4 2024 to US$19.2b in Q1 2025 and US$20.3b in Q1 2026, while quarterly EPS has shifted from US$1.45 to US$1.41 and now US$1.62. This...

Bitmine Immersion Technologies (BMNR) has stepped into Q2 2026 with Q1 figures that put its earnings profile front and center, posting total revenue of US$2.3 million and a basic EPS loss of US$15.98, alongside a net loss of about US$5.2 billion excluding extra items. Over the past year, the company has seen quarterly revenue move from US$0.7 million in Q4 2024 to US$1.2 million in Q1 2025 and US$2.3 million in Q1 2026. Over the same period, EPS has swung from a loss of US$0.33 in Q4 2024 to...

Sally Beauty Holdings (SBH) drew fresh investor attention after appointing Adrianne Lee as Chief Financial Officer and Senior Vice President, replacing Marlo Cormier. The transition is scheduled to be completed in late April 2026. See our latest analysis for Sally Beauty Holdings. Despite the CFO transition capturing attention, recent share price returns have been softer, with a 90 day share price return of a 13.22% decline contrasting with a 1 year total shareholder return of 72.16%. This...

Credit Acceptance is drawing attention for sluggish growth and a relatively high debt load. Recent analysis points to stagnating revenue and earnings over the long term, raising questions about profit generation. These concerns focus on the company’s ability to comfortably service its borrowings and sustain shareholder value. For investors tracking NasdaqGS:CACC, the discussion around growth and leverage comes at a time when the stock trades at $497.36, with a 7 day return of 6.4% and a 30...

Over the last 7 days, the United States market has risen by 3.4%, contributing to a remarkable 35% increase over the past year, with earnings forecasted to grow by 16% annually. In this buoyant environment, identifying stocks that are potentially undervalued yet exhibit insider action can be an intriguing strategy for investors seeking opportunities within the small-cap segment.

The United States market has shown robust growth, rising 3.4% over the last week and climbing 35% in the past year, with earnings projected to increase by 16% annually. In such a thriving environment, identifying undervalued stocks can present opportunities for investors seeking to capitalize on potential gains while navigating current market conditions.

Somnigroup International has agreed to acquire Leggett & Platt in an all stock transaction valued at $2.5 billion. Leggett & Platt shareholders are set to receive Somnigroup stock, with Leggett & Platt continuing as a standalone business unit. The deal has unanimous board approval and is targeted to close by year end 2026, subject to shareholder and regulatory approvals. For investors watching NYSE:LEG, this deal comes as the stock trades around $11.35 after a mixed longer term record. The...

Westlake Corporation has entered into a settlement agreement with direct purchaser plaintiffs in the PVC Pipe Antitrust Litigation, agreeing to pay US$67 million, subject to court approval, while related indirect purchaser claims remain unresolved. This settlement helps clarify a key legal overhang tied to Westlake’s PVC pipe and fittings business, an important part of its Housing and Infrastructure Products segment. We will now examine how resolving a significant portion of this antitrust...

The United States market has shown robust performance with a 3.4% climb in the last week and a 35% increase over the past year, while earnings are anticipated to grow by 16% annually in the coming years. In this thriving environment, growth companies with high insider ownership can be particularly appealing as they often indicate strong confidence from those closest to the business, potentially aligning well with investor interests.

Over the last 7 days, the United States market has risen 3.4%, and over the past year, it's up by an impressive 35%, with earnings forecasted to grow by 16% annually. For investors willing to explore beyond well-known companies, penny stocks—often representing smaller or newer enterprises—can offer intriguing opportunities. Despite their vintage label, these stocks can present underappreciated growth potential at lower price points when backed by strong balance sheets and solid fundamentals.

The United States market has shown robust performance recently, climbing 3.4% in the last week and surging 35% over the past year, with earnings projected to grow by 16% annually in the coming years. In such a dynamic environment, identifying small-cap stocks with strong fundamentals and growth potential can be key to uncovering promising investment opportunities.

The United States market has shown impressive growth, rising 3.4% in the last week and 35% over the past year, with earnings projected to grow by 16% annually in the coming years. In this thriving environment, dividend stocks like Paychex stand out as they offer both potential income through dividends and stability amidst market fluctuations.

The Morning Bull - US Market Morning Update Thursday, Apr, 16 2026 US stock futures are slightly higher this morning, with E‑mini S&P 500 contracts up about 0.1%, as investors weigh steady borrowing costs against fresh signals on inflation and growth. The 10 year US Treasury yield sits near 4.27%, which suggests markets still see the Federal Reserve keeping interest rates unchanged. As a result, mortgage rates and credit card costs may stay elevated for longer. At the same time, US import...

This article walks through the key signals behind Pilgrim's Pride at around US$33.64 so you can consider whether it is starting to look like value or still has risk priced in. The share price has seen pressure recently, with returns of 6.4% over 7 days, 8.4% over 30 days and 15.6% year to date. It is still sitting on gains of 73.7% over 3 years and 60.3% over 5 years, while the past 12 months show a 34.0% decline. Recent coverage has focused on how investors are reassessing poultry...

Federated Hermes, NYSE:FHI, has acquired an 80% interest in FCP Fund Manager. The deal marks a major expansion into U.S. real estate and alternative investments. The move reflects a wider push to grow private markets exposure alongside traditional asset management. Federated Hermes enters this transaction with its shares at $58.0, after a 59.2% return over the past year and 133.5% over the past 5 years. The company already has an established position in asset management, and this deal adds...

Recent share performance and earnings profile Novanta (NOVT) has attracted investor attention after a period of mixed share performance, with a month gain of 7.2% contrasted by a 5.1% decline over the past 3 months. At a last close of US$126.45 and a market value of about US$4.6b, the company reports annual revenue of US$980.6m and net income of US$53.8m. The reported annual revenue and net income growth rates are 6.3% and 33.9% respectively. See our latest analysis for Novanta. Recent moves...

Silence Therapeutics plc ( NASDAQ:SLN ) insiders who purchased shares in the last 12 months were richly rewarded last...

We wouldn't blame MoonLake Immunotherapeutics ( NASDAQ:MLTX ) shareholders if they were a little worried about the fact...

AerCap Holdings appointed Doug Parker as a Non Executive Director to its board, bringing in a former airline industry leader. The change follows the latest AGM, which included the retirement of Julian (Brad) Branch and the re appointment of several other directors. The moves indicate ongoing board refresh at NYSE:AER that could influence future oversight and decision making. AerCap Holdings, trading on the NYSE under ticker NYSE:AER, last closed at $147.24. The stock shows a 56.3% return...

Atkore (ATKR) is back on investors’ radar after recent share moves, with the stock up around 21% over the past month but down about 4% over the past 3 months. See our latest analysis for Atkore. That recent 20.5% 1 month share price return contrasts with a 4.5% 3 month share price decline and a 19.7% 1 year total shareholder return, suggesting momentum has picked up again after a weaker stretch. If Atkore’s rebound has your attention and you want to see what else is moving around power...

Mama's Creations (MAMA) just closed FY 2026 with fourth quarter revenue of US$54.0 million and EPS of US$0.05, capping a year where trailing 12 month revenue reached US$171.7 million and EPS came in at US$0.14. The company has seen quarterly revenue move from US$33.6 million in Q4 FY 2025 to US$54.0 million in Q4 FY 2026, alongside EPS shifting from US$0.04 to US$0.05 over the same period. This is setting up a results season in which investors are closely watching how efficiently that revenue...

If you are wondering whether Zimmer Biomet Holdings at around US$94.20 offers good value today, the key is understanding what the current price actually reflects. The stock has returned 1.3% over the last 7 days, 1.0% over the last 30 days, 4.6% year to date and shows a 1.8% decline over the last year, alongside deeper 3 year and 5 year declines of 29.9% and 42.7%. These mixed returns come as the company continues to attract attention for its position in orthopedics and related medical...